A major investment opportunity lies in companies that use AI to extract the full information density from routine medical procedures. For example, analyzing a mammogram not just for cancer but also for arterial calcification, which indicates cardiovascular risk—a critical learning that is currently often discarded.

A major cause of clinical trial failure is unforeseen toxicity. By creating AI-powered models based on single-cell atlases, researchers can predict which unintended cells express a drug's target receptor. This allows them to anticipate side effects, like kidney toxicity, in silico, saving billions in failed drug development.

As AI enables early disease prediction (like Grail's cancer test), the number of sick patients will decrease. This erodes the traditional drug sales model, forcing pharma companies to create new revenue streams by monetizing predictive data and insights.

AI platforms can analyze existing medical images, like CT scans ordered for a cough, to find subtle, early signs of cancers. This repurposes vast amounts of routine diagnostic data into a powerful, passive screening tool, allowing for incidental discoveries of diseases like pancreatic cancer without new procedures.

With over 5,000 oncology drugs in development and a 9-out-of-10 failure rate, the current model of running large, sequential clinical trials is not viable. New diagnostic platforms are essential to select drugs and patient populations more intelligently and much earlier in the process.

Current patient selection for radioligand therapies often relies on a simple binary 'positive' or 'negative' assessment, which fails to predict response 55% of the time. AI moves beyond this by providing quantitative, whole-body tumor assessments to predict who will actually respond to treatment, a far more critical factor for clinical and commercial success.

The progress of AI in predicting cancer treatment is stalled not by algorithms, but by the data used to train them. Relying solely on static genetic data is insufficient. The critical missing piece is functional, contextual data showing how patient cells actually respond to drugs.

The pharmaceutical industry risks repeating Kodak's failure of inventing but ignoring a disruptive technology. For Kodak, it was digital photography; for pharma, it's AI. The industry possesses vast amounts of data (the new 'film'), but the real danger lies in failing to embrace the AI-driven intelligence layer that can interpret and act on it.

AI is no longer a 'nice-to-have' for radioligand therapies. It is essential for precise patient selection and response monitoring. Without AI-driven confidence in outcomes, the commercial viability, adoption, and reimbursement for these expensive new treatments are at risk, making it a prerequisite for commercial success.